Skip to main content


Details of the Drug
Generic Name:
Drug Type:
Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager
How the Drug is Given:

Injection, for subcutaneous use


Indications and Usage

Elranatamab-bcmm is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Side effects needing medical attention

Most common adverse reactions are cytokine release syndrome (CRS), fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, and fever. The most common laboratory abnormalities are decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased white blood cells, and decreased platelets. 

For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.